DHFR and pemphigus: Importantly, CellAwareGNN prioritizes promising repurposing candidates, including Ocrelizumab for Pemphigus via CD20-expressing B cells, Methotrexate for Pemphigus through DHFR and ATIC activity in T and B cells, and Rosiglitazone for Rheumatoid Arthritis through PPAR- γ activation.